Immunologic Factors: all 3,292 studies that test it
Page 31 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell CarcinomaWithdrawnNCT00176280Phase 2
- Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant RecipientsCompletedNCT00176059Early Phase 1
- Pneumococcal Vaccination of Fiji InfantsCompletedNCT00170612Phase 2
- Vaccination of Children Following Allogeneic Stem Cell TransplantationCompletedNCT00169728Phase 3
- Pneumococcal Adult-dose Ranging Immunization StudyCompletedNCT00169234Phase 1/2
- Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's LymphomaCompletedNCT00169208Phase 2
- Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell LymphomaTerminatedNCT00169169Phase 3
- A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic LymphomaCompletedNCT00169156Phase 2
- Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell LymphomaCompletedNCT00169143Phase 2
- Community Based Trial for AMEVIVE®CompletedNCT00168753Phase 4
- Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)CompletedNCT00168740Phase 3
- Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168025Phase 3
- Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168012Phase 3
- Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney TransplantWithdrawnNCT00167791Not applicable
- Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic AmyloidosisCompletedNCT00166413Phase 2
- Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00165477Phase 2
- Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic PurpuraCompletedNCT00162006Phase 2
- Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)CompletedNCT00161993Phase 2
- A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan AloneWithdrawnNCT00161564Phase 2
- Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency DisordersCompletedNCT00157079Phase 3
- Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00153933Phase 1
- Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00152139Phase 3
- Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple MyelomaCompletedNCT00151203Phase 2
- Rituximab in the Treatment of Graves' DiseaseCompletedNCT00150111Phase 1/2
- Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.WithdrawnNCT00149019Phase 2
- Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's LymphomaCompletedNCT00147953Phase 2
- Haploidentical Stem Cell Transplant for Treatment Refractory Hematological MalignanciesCompletedNCT00145613Phase 2
- ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell LymphomaCompletedNCT00144807Phase 2
- Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's LymphomaCompletedNCT00143871Phase 2
- Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00143065Phase 2
- Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's MacroglobulinemiaCompletedNCT00142155Not applicable
- Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's LymphomaTerminatedNCT00141700Phase 2
- ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell LymphomaTerminatedNCT00140660Phase 3
- ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1CompletedNCT00140595Phase 3
- Primary Rituximab and MaintenanceCompletedNCT00140582Phase 3
- Early Versus Delayed Pneumococcal Vaccination in HIVCompletedNCT00137605Phase 1/2
- Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor BurdenCompletedNCT00136552Phase 3
- Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host DiseaseCompletedNCT00136396Phase 1/2
- A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen PlanusTerminatedNCT00135733Phase 2
- Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.Status unknownNCT00131313Phase 4
- Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on ChemotherapyTerminatedNCT00127569Phase 2
- Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's LymphomaTerminatedNCT00126243Phase 2
- Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar RadiculopathyCompletedNCT00120120Phase 2/3
- Chemotherapy Followed by Zevalin for Relapsed Mantle Cell LymphomaCompletedNCT00119730Phase 2
- Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaCompletedNCT00117975Phase 2
- Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant RejectionCompletedNCT00117689Phase 2
- Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular LymphomaCompletedNCT00115700Phase 3
- Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaCompletedNCT00112931Phase 3
- Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's LymphomaWithdrawnNCT00110006Not applicable
- Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic SyndromesCompletedNCT00104962Phase 1
- Anti-CD20 Antibody Therapy for Sjogren's SyndromeCompletedNCT00101829Phase 1
- Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
- Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00100737Phase 2
- 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNCT00098488Phase 1
- Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00097760Phase 2
- A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple SclerosisCompletedNCT00097188Phase 2
- Lenalidomide in Treating Patients With Advanced or Unresectable Kidney CancerCompletedNCT00096525Phase 2
- Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00093769Phase 2
- Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy IICompletedNCT00093028Phase 3
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingNCT00092222Phase 2
- Rituximab to Treat Stiff Person SyndromeCompletedNCT00091897Phase 2
- A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)CompletedNCT00091624Phase 1
- Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid TumorsCompletedNCT00091052Phase 1/2
- Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%TerminatedNCT00090194Phase 2
- Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00090038Phase 4
- Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV MelanomaCompletedNCT00089193Phase 2
- Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaTerminatedNCT00089115Phase 3
- Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for MelanomaCompletedNCT00089063Phase 2
- Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00087425Phase 2
- Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell TransplantationTerminatedNCT00087009Phase 1
- Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00086944Phase 1/2
- Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00086775Phase 2
- Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)CompletedNCT00086203Phase 2
- VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT00085696Phase 2
- Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV MelanomaWithdrawnNCT00085579Phase 2
- Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular MelanomaCompletedNCT00085306Phase 2
- Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS LymphomaCompletedNCT00082836Not applicable
- Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the UrotheliumCompletedNCT00082719Phase 1
- Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's LymphomaCompletedNCT00080886Phase 2
- FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaTerminatedNCT00079443Phase 2
- Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast CancerCompletedNCT00079157Phase 1
- A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's DiseaseCompletedNCT00078611Phase 3
- A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid ArthritisCompletedNCT00077870Phase 1/2
- SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00076349Phase 2
- Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid ArthritisCompletedNCT00074438Phase 2
- Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)CompletedNCT00072722Phase 2
- An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard TherapiesCompletedNCT00072592Phase 1
- Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial TreatmentCompletedNCT00072579Phase 2
- Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLLCompletedNCT00072007Phase 2
- Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's LymphomaCompletedNCT00071955Phase 2
- Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT00070447Phase 2
- Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaCompletedNCT00070083Phase 1
- Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain TumorCompletedNCT00069940Phase 1
- Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
- A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)CompletedNCT00067743Phase 2
- Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT00065351Phase 2
- Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic SyndromesCompletedNCT00064974Phase 2
- Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisorderCompletedNCT00064246Phase 1/2
- Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate CancerCompletedNCT00064129Phase 1
- Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's LymphomaCompletedNCT00064116Phase 3